Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
Status:
Withdrawn
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Two-part phase 1B clinical trial combining cextuximab and savolitinib for treating Ras
wild-type colorectal cancer (CRC). Part 1 will assess the safety and tolerability of this
drug combination and will include patients with squamous cell carcinoma of the head and neck
cancer, as well as patients with CRC. Part 2 of the study, the focus of this registration,
will obtain further safety data for the combination of cextuximab and savolitinib and will
look at the efficacy of cextuximab and savolitinib in Ras wild-type mCRC that was previously
treated and relapsed on cetuximab or panitumumab.Correlative studies will examine tumor and
blood specimens for mechanisms of anti-EGFR resistance and response to MET inhibition.